Fancg: A Potential Drug Target and Biomarker for Various Diseases

Target Name: FANCG

NCBI ID: G2189

FANCG

Fancg: A Potential Drug Target and Biomarker for Various Diseases

Fancg (FAN-CJ) is a protein that is expressed in various tissues of the body, including the brain, heart, and kidneys. It is a member of the superfamily of cytoskeletal proteins, known as the histamine receptor-associated protein (HAP) family. Fancg plays a critical role in the regulation of cellular processes, including cell signaling, inflammation, and stress responses.

Recent studies have identified Fancg as a potential drug target and biomarker for various diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. In this article, we will explore the biology and potential therapeutic applications of Fancg, with a focus on its role as a drug target and biomarker.

Fancg: Structure and Function

Fancg is a 21-kDa protein that is expressed in a variety of tissues, including the brain, heart, and kidneys. It is highly conserved, with a calculated pI of 5.5 and a predicted localization in the cytoplasm. Fancg has a unique structure, with a catalytic core and a transmembrane region that is involved in its function.

The catalytic core of Fancg is the region that is responsible for the binding of small molecules, such as drugs and toxins. This core is composed of a nucleotide-binding oligomerization domain (NBD) and a protein-coding region (PCR). The NBD is a nucleotide-binding domain that is responsible for binding to small nucleotides, while the PCR is a region that contains the amino acid sequence responsible for the catalytic activity of the protein.

The transmembrane region of Fancg is responsible for its ability to interact with various cellular signaling pathways. This region is composed of a unique protein that is involved in the regulation of the cytoskeleton and is composed of multiple domains, including a leucine-rich repeat (LRR), a calbindin-like protein (CALBP), and a carboxy-terminal protein (CTP).

Fancg functions as a negative regulator of the cytoskeleton, which is involved in the regulation of cell shape and movement. It does this by interacting with several other proteins, including the cytoskeleton-associated protein (CAP), which is involved in the regulation of cell division, and the scaffold protein (SPG), which is involved in the regulation of cell-cell adhesion.

In addition to its role in regulating the cytoskeleton, Fancg is also involved in the regulation of cellular signaling pathways. It is a negative regulator of several signaling pathways, including the TGF-β pathway, the PI3K/Akt pathway, and the NF-kappa-B pathway.

Fancg as a Drug Target

Fancg has been identified as a potential drug target for a variety of diseases, including cancer, neurodegenerative diseases, and autoimmune disorders.

In cancer, Fancg has been shown to be involved in the regulation of cell growth, apoptosis, and angiogenesis. It has been shown to play a critical role in the development and progression of several types of cancer, including breast cancer, lung cancer, and colorectal cancer.

In neurodegenerative diseases, Fancg has been shown to be involved in the regulation of neurotransmitter signaling and cell survival. It has been shown to play a critical role in the development and progression of neurodegenerative diseases, including Alzheimer's disease, Parkinson's disease, and Huntington's disease.

In autoimmune disorders, Fancg has been shown to be involved in the regulation of immune cell function and tolerance. It has been shown to play

Protein Name: FA Complementation Group G

Functions: DNA repair protein that may operate in a postreplication repair or a cell cycle checkpoint function. May be implicated in interstrand DNA cross-link repair and in the maintenance of normal chromosome stability. Candidate tumor suppressor gene

The "FANCG Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about FANCG comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets